Athersys to ask Nasdaq for another reprieve on delisting its stock
April 20, 2023 at 15:15 PM EDT
Cleveland regenerative medicine startup has been restructuring to cut costs since mid-2022 while raising money to complete clinical trials of its MultiStem adult stem cell therapy.
